Hills RK - Search Results

1

Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia.

Linch DC, Hills RK, Gilkes A, Burnett AK, Russell N, Gale RE. Linch DC, et al. Among authors: hills rk. Leuk Res. 2021 Sep;108:106553. doi: 10.1016/j.leukres.2021.106553. Epub 2021 Mar 2. Leuk Res. 2021. PMID: 33706968

2

Incidence and prognostic significance of C-MPL expression in acute myeloid leukemia.

Chelvatheebam S, Langabeer SE, Linch DC, Hills RK, Greenwell P. Chelvatheebam S, et al. Among authors: hills rk. Leuk Res. 2003 Sep;27(9):869-70. doi: 10.1016/s0145-2126(03)00016-x. Leuk Res. 2003. PMID: 12804647 No abstract available.

3

Impact of karyotype on treatment outcome in acute myeloid leukemia.

Grimwade D, Moorman A, Hills R, Wheatley K, Walker H, Harrison G, Harrison Ch, Goldstone A, Burnett A; NCRI Adult Leukaemia Working Party. Grimwade D, et al. Ann Hematol. 2004;83 Suppl 1:S45-8. doi: 10.1007/s00277-004-0849-8. Ann Hematol. 2004. PMID: 15124668 Review.

4

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.

Bowen DT, Frew ME, Hills R, Gale RE, Wheatley K, Groves MJ, Langabeer SE, Kottaridis PD, Moorman AV, Burnett AK, Linch DC. Bowen DT, et al. Blood. 2005 Sep 15;106(6):2113-9. doi: 10.1182/blood-2005-03-0867. Epub 2005 Jun 9. Blood. 2005. PMID: 15951308 Free article.

5

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

Gale RE, Hills R, Kottaridis PD, Srirangan S, Wheatley K, Burnett AK, Linch DC. Gale RE, et al. Blood. 2005 Nov 15;106(10):3658-65. doi: 10.1182/blood-2005-03-1323. Epub 2005 Aug 2. Blood. 2005. PMID: 16076872 Free article.

6

Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.

Gale RE, Hills R, Pizzey AR, Kottaridis PD, Swirsky D, Gilkes AF, Nugent E, Mills KI, Wheatley K, Solomon E, Burnett AK, Linch DC, Grimwade D; NCRI Adult Leukaemia Working Party. Gale RE, et al. Blood. 2005 Dec 1;106(12):3768-76. doi: 10.1182/blood-2005-04-1746. Epub 2005 Aug 16. Blood. 2005. PMID: 16105978 Free article.

7

Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials.

Gibson BE, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK, De Graaf SS, Harrison CJ. Gibson BE, et al. Among authors: hills rk. Leukemia. 2005 Dec;19(12):2130-8. doi: 10.1038/sj.leu.2403924. Leukemia. 2005. PMID: 16304572 Clinical Trial.

8

Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.

Rao A, Hills RK, Stiller C, Gibson BE, de Graaf SS, Hann IM, O'Marcaigh A, Wheatley K, Webb DK. Rao A, et al. Among authors: hills rk. Br J Haematol. 2006 Mar;132(5):576-83. doi: 10.1111/j.1365-2141.2005.05906.x. Br J Haematol. 2006. PMID: 16445830 Free article. Clinical Trial.

9

Long-term results of the MRC AML10 trial.

Burnett AK, Wheatley K, Goldstone AH, Stevens R, Hann I, Hills RK. Burnett AK, et al. Among authors: hills rk. Clin Adv Hematol Oncol. 2006 Jun;4(6):445-51. Clin Adv Hematol Oncol. 2006. PMID: 16981667 Clinical Trial. No abstract available.

10

Problems with up-front randomization in clinical trials.

Wheatley K, Hills RK, Burnett AK. Wheatley K, et al. Among authors: hills rk. J Clin Oncol. 2006 Dec 1;24(34):5471-2; author reply 5472-3. doi: 10.1200/JCO.2006.08.3048. J Clin Oncol. 2006. PMID: 17135654 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

203 results

Search Page